Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages

Journal of Cellular Physiology

Volumn 227, Issue 5, 2012, Pages 1829-1837

  Secchiero, Paola ^a   Rimondi, Erika ^a   di Iasio, Maria Grazia ^a   Voltan, Rebecca ^a   Gonelli, Arianna ^a   Zauli, Giorgio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; MESSENGER RNA; NUTLIN 3; PROTEIN P53;

ARTICLE; CELL ADHESION; CELL MIGRATION; CLINICAL ARTICLE; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MACROPHAGE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ACTINS; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; FIBROBLASTS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID; MACROPHAGES; MESENCHYMAL STEM CELLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856188228     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22910     Document Type: Article

References (40)

1. Bellini A, Mattoli S. 2007. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 87: 858-870.
2. Comer KA, Dennis PA, Armstrong L, Catino JJ, Kastan MB, Kumar CC. 1998. Human smooth muscle α-actin gene is a transcriptional target of the p53 tumor suppressor protein. Oncogene 16: 1299-1308.
3. 133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160: 3891-3898.
4. Herman IM, Crisona NJ, Pollard TD. 1981. Relation between cell activity and the distribution of cytoplasmic actin and myosin. J Cell Biol 90: 84-91.
5. Herzog EL, Bucala R. 2010. Fibrocytes in health and disease. Exp Hematol 38: 548-556.
6. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat Rev Cancer 6: 392-401.
7. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M. 2005. MDM2 antagonists induce p53-dependent apoptosis in AML: Implications for leukemia therapy. Blood 106: 3150-3159.
8. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreef M. 2007. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic funcion of p53 in acute myelogenous leukemia cells. Cancer Res 67: 3210-3219.
9. Kumar CC, Bushel P, Mohan-Peterson S, Ramirez F. 1992. Regulation of smooth muscle alpha-actin promoter in ras-transformed cells: Usefulness for setting up reporter gene-based assay system for drug screening. Cancer Res 52: 6877-6884.
10. Kumar CC, Kim JH, Bushel P, Armstrong L, Catino JJ. 1995. Activation of smooth muscle alpha-actin promoter in ras-transformed cells by treatments with antimitotic agents: Correlation with stimulation of SRF:SRE mediated gene trascription. J Biol Chem 118: 1285-1292.
11. Leavitt J, Gunning P, Kedes L, Jariwalla R. 1985. Smooth muscle α-actin is a transformation-sensitive marker for mouse NIH 3T3 and Rat-2cells. Nature 316: 840-842.
12. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H, Wang S, Malek SN. 2010. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 116: 71-80.
13. Manapov F, Muller P, Rychly J. 2005. Translocation of p21(Cip1/WAF1) from the nucleus to the cytoplasm correlates with pancreatic myofibroblast to fibroblast cell conversion. Gut 54: 814-822.
14. Mattoli S, Bellini A, Schmidt M. 2009. The role of a human hematopoietic mesenchymal progenitor in wound healing and fibrotic diseases and implications for therapy. Curr Stem Cell Res Ther 4: 266-280.
15. Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P, Capitani S, Secchiero P. 2003. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86: 126-135.
16. Mitani N, Niwa Y, Okamoto Y. 2007. Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem 44: 557-559.
17. Molteni A, Wolfe LF, Ward WF, Ts'ao CH, Molteni LB, Veno P, Fish BL, Taylor JM, Quintanilla N, Herndon B, Moulder JE. 2007. Effect of angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr Pharm Des 13: 1307-1316.
18. Moran DM, Maki CG. 2010. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther 9: 895-905.
19. Mori L, Bellini A, Stacey MA, Schmidt M, Mattoli S. 2005. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res 304: 81-90.
20. Nakashima N, Kuwano K, Maeyama T, Hagimoto N, Yoshimi M, Hamada N, Yamada M, Nakanishi Y. 2005. The p53-Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. J Clin Pathol 58: 583-589.
21. Nelson A, Mendoza T, Hoyle GW, Brody AR, Fermin C, Morris GF. 2001. Enhancement of fibrogenesis by the p53 tumor suppressor protein in asbestos-exposed rodents. Chest 120: 33S-34S.
22. Owens GK, Thompson MM. 1986. Developmental changes in isoactin expression in rat aortic smooth muscle cells in vivo. Relationship between growth and cytodifferentiation. J Biol Chem 261: 13373-13380.
23. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. 2004. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114: 438-446.
24. Pilling D, Fan T, Huang D, Kaul B, Gomer RH. 2009. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE 4: e7475.
25. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. 2004. Circulating fibrocytes: Collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 36: 598-606.
26. Rønnov-Jessen L, Petersen OW. 1996. A function for filamentous alpha-smooth muscle actin: Retardation of motility in fibroblasts. J Cell Biol 134: 67-80.
27. Roy S, Khanna S, Rink T, Radtke J, Williams WT, Biswas S, Schnitt R, Strauch AR, Sen CK. 2007. P21waf1/cip1/sdi1 as a central regulator of inducible smooth muscle actin expression and differentiation of cardiac fibroblasts to myofibroblasts. Mol Biol Cell 18: 4837-4846.
28. Secchiero P, Sun D, De Vico AL, Crowley RW, Reitz MS, Zauli G, Lusso P, Gallo RC. 1997. Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. J Virol 71: 4571-4580.
29. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G. 2005. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105: 3413-3419.
30. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G. 2007a. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8: 395-403.
31. Secchiero P, Zerbinati C, Melloni E, Milani D, Campioni D, Fadda R, Tiribelli M, Zauli G. 2007b. The MDM-2 antagonist Nutlin-3 promotes maturation of acute myeloid leukemic blasts. Neoplasia 9: 853-861.
32. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S, Albini A, Zauli G. 2007c. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100: 61-69.
33. Secchiero P, di Iasio MG, Gonelli A, Zauli G. 2008a. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 14: 2100-2110.
34. Secchiero P, Corallini F, Rimondi E, Chiaruttini C, di Iasio MG, Rustighi A, Del Sal G, Zauli G. 2008b. Activation of the p53 pathway down-regulates the osteoprotegerin (OPG) expression and release by vascular endothelial cells. Blood 111: 1287-1294.
35. Secchiero P, Melloni E, di Iasio MG, Tiribelli M, Rimondi E, Corallini F, Gattei V, Zauli G. 2009. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood 113: 4300-4308.
36. Shao DD, Suresh R, Vakil V, Gomer RH, Pilling D. 2008. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fi{ligature}brocyte differentiation. J Leukoc Biol 83: 1323-1333.
37. Thompson T, Andreeff M, Studzinski GP, Vassilev LT. 2010. 1, 25-Dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53. Mol Cancer Ther 9: 1158-1168.
38. Vassilev LT. 2007. MDM2 inhibitors for cancer therapy. Trends Mol Med 13: 23-31.
39. Zauli G, Re MC, Furlini G, Giovannini M, La Placa M. 1992. Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 73: 417-421.
40. Zhang L, Yan Y, Zhu D, Yang W, Wang W, Hu Y, Yang B, He Q. 2011. Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells. Invest New Drugs 2010 August 5 [Epub ahead of print]. DOI: 10.1007/s10637-010-9512-5.